Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cornelia Koch

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Biochimica Et Biophysica Acta|June 21, 2011
Ligand-induced fit affects binding modes and provokes changes in crystal packing of aldose reductaseCornelia Koch, Andreas Heine, Gerhard Klebe
Journal of Molecular Biology|December 28, 2010
Tracing the detail: how mutations affect binding modes and thermodynamic signatures of closely related aldose reductase inhibitorsCornelia Koch, Andreas Heine, Gerhard Klebe
Current Medical Research and Opinion|April 14, 2015
Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week studyThomas Forst, Cornelia Koch, Markus Dworak
Journal of Synchrotron Radiation|August 25, 2011
Radiation damage reveals promising interaction positionCornelia Koch, Andreas Heine, Gerhard Klebe
Cardiovascular Diabetology|January 24, 2018
Individualised treatment targets in patients with type-2 diabetes and hypertensionRoland E Schmieder, Diethelm Tschöpe, Cornelia Koch, et al.
BMC Endocrine Disorders|May 3, 2015
Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registryRoland E Schmieder, Anselm K Gitt, Cornelia Koch, et al.
Angewandte Chemie (International Ed. in English)|March 31, 2007
How reliable are current docking approaches for structure-based drug design? Lessons from aldose reductaseMatthias Zentgraf, Holger Steuber, Cornelia Koch, et al.
International Journal of Cardiology|October 10, 2022
Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registryLars H Lund, Uwe Zeymer, Andrew L Clark, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|March 16, 2021
Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registryUwe Zeymer, Andrew L Clark, Vivencio Barrios, et al.
ESC Heart Failure|September 15, 2022
Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registryAldo P Maggioni, Andrew L Clark, Vivencio Barrios, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Biochimica Et Biophysica Acta|June 21, 2011
Ligand-induced fit affects binding modes and provokes changes in crystal packing of aldose reductaseCornelia Koch, Andreas Heine, Gerhard Klebe
Journal of Molecular Biology|December 28, 2010
Tracing the detail: how mutations affect binding modes and thermodynamic signatures of closely related aldose reductase inhibitorsCornelia Koch, Andreas Heine, Gerhard Klebe
Current Medical Research and Opinion|April 14, 2015
Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week studyThomas Forst, Cornelia Koch, Markus Dworak
Journal of Synchrotron Radiation|August 25, 2011
Radiation damage reveals promising interaction positionCornelia Koch, Andreas Heine, Gerhard Klebe
Cardiovascular Diabetology|January 24, 2018
Individualised treatment targets in patients with type-2 diabetes and hypertensionRoland E Schmieder, Diethelm Tschöpe, Cornelia Koch, et al.
BMC Endocrine Disorders|May 3, 2015
Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registryRoland E Schmieder, Anselm K Gitt, Cornelia Koch, et al.
Angewandte Chemie (International Ed. in English)|March 31, 2007
How reliable are current docking approaches for structure-based drug design? Lessons from aldose reductaseMatthias Zentgraf, Holger Steuber, Cornelia Koch, et al.
International Journal of Cardiology|October 10, 2022
Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registryLars H Lund, Uwe Zeymer, Andrew L Clark, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|March 16, 2021
Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registryUwe Zeymer, Andrew L Clark, Vivencio Barrios, et al.
ESC Heart Failure|September 15, 2022
Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registryAldo P Maggioni, Andrew L Clark, Vivencio Barrios, et al.
Pageof 2